No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 17 of the 40 quarters in the window, leaving 23 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 6.0x · 10Y median 14.0x · 33rd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:01:04.783Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T12:01:04.783Z. Latest historical point 2025-03-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T12:01:04.783Z. Latest historical point 2025-03-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T12:01:04.783Z. Latest historical point 2026-10-05.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:01:04.783Z. Latest historical point 2025-03-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:01:04.783Z. Latest historical point 2025-03-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Assembly Biosciences, Inc. (ASMB) stock was $22.74 as of Oct 5, 2026, 4:00 PM EDT, up 0.89% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -2.5% · 3-year avg +33.9%/yr · 5-year avg -10.7%/yr
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.66
Revenue Est.
$9.07M
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.67
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ASMB | $450.64M | $22.74 | +0.89% | -2.48% | -10.66% | -13.41% | N/A |
| 2DMAC | $453.70M | $8.42 | +2.31% | +19.00% | +16.41% | +7.89% | vs ASMB |
| 3CAPR | $447.43M | $7.78 | -13.07% | -0.39% | +15.17% | -13.84% | vs ASMB |
| 4NRC | $468.31M | $20.78 | +2.11% | +75.54% | -11.49% | +4.93% | vs ASMB |
| 5CERS | $471.57M | $2.34 | +2.63% | +48.76% | -17.30% | -9.37% | vs ASMB |
| 6EDIT | $428.16M | $2.79 | +6.49% | -28.71% | -40.76% | -15.75% | vs ASMB |
$13.37M
vs Estimate
$8.60M
Consensus Rating
Based on 5 analysts
Average Price Target
$52.00
+128.7% upside
Low
$43.00
Current
$22.74
High
$62.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.66 | $-0.66 | $-0.66 | 2 |
| Quarter ending Dec 2026 | $0.48 | $0.48 | $0.48 | 2 |
| Quarter ending Mar 2027 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Quarter ending Jun 2027 | $-1.03 | $-1.03 | $-1.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.03 | $-0.61 | $-0.23 | 3 |
| FY 2027 | $-5.19 | $-3.05 | $-1.15 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $9.07M | $9.07M | $9.07M | 3 |
| Quarter ending Dec 2026 | $43.14M | $43.14M | $43.14M | 3 |
| Quarter ending Mar 2027 | $10.55M | $10.55M | $10.55M | 1 |
| Quarter ending Jun 2027 | $2.00M | $2.00M | $2.00M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $20.36M | $63.43M | $106.49M | 4 |
| FY 2027 | $22.21M | $42.65M | $65.64M | 3 |
